Concepts (232)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Benzhydryl Compounds | 2 | 2021 | 240 | 0.89 | Why? |
| Quality Improvement | 3 | 2018 | 2435 | 0.86 | Why? |
| Glucosides | 2 | 2021 | 359 | 0.81 | Why? |
| Gastric Bypass | 2 | 2017 | 152 | 0.71 | Why? |
| Blood Pressure | 4 | 2019 | 2198 | 0.67 | Why? |
| Purinergic P2Y Receptor Antagonists | 2 | 2019 | 206 | 0.66 | Why? |
| Chlorthalidone | 2 | 2018 | 7 | 0.65 | Why? |
| Fibrinolytic Agents | 2 | 2018 | 1702 | 0.63 | Why? |
| Amiloride | 2 | 2018 | 35 | 0.63 | Why? |
| Acute Coronary Syndrome | 3 | 2019 | 2107 | 0.61 | Why? |
| Ischemic Attack, Transient | 1 | 2018 | 439 | 0.54 | Why? |
| Multicenter Studies as Topic | 4 | 2021 | 2437 | 0.54 | Why? |
| Diuretics | 2 | 2018 | 326 | 0.53 | Why? |
| Percutaneous Coronary Intervention | 4 | 2019 | 3646 | 0.53 | Why? |
| Medication Adherence | 3 | 2018 | 1270 | 0.49 | Why? |
| Brazil | 21 | 2021 | 12582 | 0.47 | Why? |
| Hemorrhage | 7 | 2021 | 3013 | 0.47 | Why? |
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2018 | 1510 | 0.47 | Why? |
| Azithromycin | 4 | 2021 | 3943 | 0.46 | Why? |
| Myocardial Infarction | 5 | 2019 | 3361 | 0.45 | Why? |
| Double-Blind Method | 10 | 2021 | 5988 | 0.44 | Why? |
| Multiple Organ Failure | 1 | 2021 | 1724 | 0.42 | Why? |
| Losartan | 1 | 2011 | 86 | 0.42 | Why? |
| ST Elevation Myocardial Infarction | 4 | 2018 | 3051 | 0.40 | Why? |
| Thrombolytic Therapy | 2 | 2018 | 2218 | 0.40 | Why? |
| Hypertension | 6 | 2021 | 8895 | 0.37 | Why? |
| Evidence-Based Medicine | 2 | 2018 | 3228 | 0.36 | Why? |
| Reminder Systems | 2 | 2018 | 104 | 0.36 | Why? |
| Troponin T | 3 | 2018 | 771 | 0.36 | Why? |
| Feedback | 3 | 2018 | 317 | 0.36 | Why? |
| Myocardial Ischemia | 4 | 2019 | 781 | 0.35 | Why? |
| Antihypertensive Agents | 4 | 2019 | 1962 | 0.35 | Why? |
| Clinical Audit | 2 | 2018 | 204 | 0.34 | Why? |
| Quality of Health Care | 2 | 2019 | 1948 | 0.34 | Why? |
| Rivaroxaban | 2 | 2021 | 467 | 0.33 | Why? |
| Cardiovascular Diseases | 5 | 2021 | 11497 | 0.32 | Why? |
| Intention to Treat Analysis | 2 | 2018 | 673 | 0.32 | Why? |
| Angiotensin II Type 1 Receptor Blockers | 1 | 2011 | 520 | 0.30 | Why? |
| Research Design | 6 | 2018 | 5830 | 0.29 | Why? |
| Platelet Aggregation Inhibitors | 4 | 2019 | 1671 | 0.28 | Why? |
| Anticoagulants | 7 | 2021 | 9563 | 0.26 | Why? |
| Enoxaparin | 2 | 2021 | 1064 | 0.26 | Why? |
| Randomized Controlled Trials as Topic | 6 | 2021 | 10649 | 0.26 | Why? |
| Atrial Fibrillation | 4 | 2019 | 2320 | 0.25 | Why? |
| Postoperative Care | 2 | 2018 | 755 | 0.24 | Why? |
| Obesity | 3 | 2019 | 7388 | 0.24 | Why? |
| Surgical Procedures, Operative | 4 | 2019 | 2662 | 0.23 | Why? |
| Telescopes | 1 | 2021 | 23 | 0.23 | Why? |
| Drug Therapy, Combination | 8 | 2021 | 7268 | 0.22 | Why? |
| Advisory Committees | 2 | 2018 | 1418 | 0.22 | Why? |
| Dexamethasone | 3 | 2020 | 2055 | 0.21 | Why? |
| Anti-Inflammatory Agents | 4 | 2021 | 6153 | 0.21 | Why? |
| Glucocorticoids | 3 | 2021 | 4431 | 0.21 | Why? |
| Cause of Death | 6 | 2021 | 4823 | 0.21 | Why? |
| Stroke | 3 | 2018 | 8839 | 0.21 | Why? |
| Case Managers | 1 | 2018 | 25 | 0.19 | Why? |
| Positive-Pressure Respiration | 2 | 2017 | 1160 | 0.19 | Why? |
| Prehypertension | 1 | 2018 | 14 | 0.19 | Why? |
| Omeprazole | 1 | 2018 | 21 | 0.18 | Why? |
| Treatment Outcome | 14 | 2021 | 51732 | 0.18 | Why? |
| Preoperative Care | 2 | 2018 | 1515 | 0.17 | Why? |
| Critical Illness | 4 | 2021 | 17281 | 0.17 | Why? |
| Postoperative Complications | 5 | 2019 | 5861 | 0.17 | Why? |
| Argentina | 2 | 2018 | 1141 | 0.17 | Why? |
| Vitamin K | 1 | 2019 | 263 | 0.16 | Why? |
| Time Factors | 8 | 2021 | 31397 | 0.16 | Why? |
| Aged | 27 | 2021 | 215776 | 0.15 | Why? |
| Case Management | 1 | 2018 | 285 | 0.15 | Why? |
| Dabigatran | 1 | 2018 | 204 | 0.15 | Why? |
| Blood Pressure Monitoring, Ambulatory | 1 | 2019 | 341 | 0.15 | Why? |
| Middle Aged | 28 | 2021 | 270681 | 0.15 | Why? |
| Sodium Chloride | 1 | 2017 | 203 | 0.15 | Why? |
| Anticholesteremic Agents | 1 | 2018 | 186 | 0.15 | Why? |
| Myocardial Revascularization | 1 | 2018 | 267 | 0.15 | Why? |
| Janus Kinase Inhibitors | 1 | 2021 | 682 | 0.15 | Why? |
| Survival Rate | 3 | 2018 | 9206 | 0.14 | Why? |
| Benchmarking | 1 | 2019 | 627 | 0.14 | Why? |
| Piperidines | 1 | 2021 | 795 | 0.14 | Why? |
| Drug Administration Schedule | 2 | 2021 | 2324 | 0.14 | Why? |
| Peru | 1 | 2018 | 1010 | 0.13 | Why? |
| Single-Blind Method | 1 | 2018 | 1283 | 0.13 | Why? |
| Male | 30 | 2021 | 367725 | 0.13 | Why? |
| Female | 30 | 2021 | 380317 | 0.13 | Why? |
| Humans | 46 | 2021 | 930598 | 0.13 | Why? |
| Pyridones | 1 | 2019 | 738 | 0.13 | Why? |
| Radial Artery | 1 | 2014 | 132 | 0.13 | Why? |
| Pyrimidines | 1 | 2021 | 1557 | 0.13 | Why? |
| Troponin | 1 | 2019 | 1058 | 0.12 | Why? |
| Vascular Surgical Procedures | 2 | 2018 | 882 | 0.12 | Why? |
| Hydroxychloroquine | 3 | 2020 | 12447 | 0.12 | Why? |
| Fluid Therapy | 1 | 2017 | 628 | 0.12 | Why? |
| Femoral Artery | 1 | 2014 | 213 | 0.12 | Why? |
| Drug Utilization | 1 | 2017 | 619 | 0.12 | Why? |
| Pulmonary Alveoli | 1 | 2017 | 867 | 0.11 | Why? |
| Weight Loss | 1 | 2017 | 826 | 0.11 | Why? |
| Kaplan-Meier Estimate | 2 | 2018 | 4260 | 0.11 | Why? |
| Algorithms | 2 | 2018 | 7346 | 0.11 | Why? |
| Proportional Hazards Models | 3 | 2018 | 6543 | 0.11 | Why? |
| Aspirin | 1 | 2019 | 1043 | 0.11 | Why? |
| Patient-Centered Care | 1 | 2019 | 860 | 0.10 | Why? |
| Education, Medical, Continuing | 1 | 2017 | 638 | 0.10 | Why? |
| Hospitals | 2 | 2021 | 11793 | 0.10 | Why? |
| Income | 1 | 2019 | 1564 | 0.10 | Why? |
| Kidney Diseases | 1 | 2021 | 1434 | 0.10 | Why? |
| Quality of Life | 2 | 2021 | 9820 | 0.09 | Why? |
| Antibodies, Monoclonal, Humanized | 2 | 2021 | 9335 | 0.09 | Why? |
| Pyrazoles | 1 | 2019 | 1791 | 0.09 | Why? |
| Dose-Response Relationship, Drug | 1 | 2018 | 3776 | 0.09 | Why? |
| Cost-Benefit Analysis | 1 | 2018 | 2259 | 0.09 | Why? |
| Heparin | 1 | 2021 | 2600 | 0.09 | Why? |
| Bariatric Surgery | 1 | 2019 | 1298 | 0.09 | Why? |
| Body Mass Index | 2 | 2019 | 4306 | 0.09 | Why? |
| Prospective Studies | 8 | 2021 | 43301 | 0.09 | Why? |
| Prognosis | 4 | 2019 | 32490 | 0.09 | Why? |
| Registries | 3 | 2017 | 12327 | 0.08 | Why? |
| Patient Education as Topic | 1 | 2017 | 1476 | 0.08 | Why? |
| Adult | 17 | 2021 | 244371 | 0.08 | Why? |
| Incidence | 5 | 2021 | 25622 | 0.08 | Why? |
| Intensive Care Units | 6 | 2021 | 29594 | 0.08 | Why? |
| Inflammation Mediators | 1 | 2017 | 2654 | 0.08 | Why? |
| Acute Disease | 1 | 2018 | 6029 | 0.07 | Why? |
| Follow-Up Studies | 6 | 2021 | 17020 | 0.07 | Why? |
| Infusions, Intravenous | 2 | 2021 | 1224 | 0.07 | Why? |
| Mortality | 1 | 2021 | 7132 | 0.07 | Why? |
| Logistic Models | 1 | 2018 | 9089 | 0.06 | Why? |
| Adrenal Cortex Hormones | 1 | 2020 | 6537 | 0.06 | Why? |
| B-Lymphocytes | 1 | 2017 | 4418 | 0.06 | Why? |
| Treatment Failure | 2 | 2020 | 2106 | 0.06 | Why? |
| Respiratory Insufficiency | 2 | 2021 | 7301 | 0.06 | Why? |
| Angiotensin Receptor Antagonists | 1 | 2018 | 3892 | 0.06 | Why? |
| Janus Kinase 3 | 1 | 2021 | 46 | 0.06 | Why? |
| Risk Factors | 7 | 2019 | 71621 | 0.06 | Why? |
| Administration, Oral | 2 | 2021 | 2340 | 0.06 | Why? |
| Respiration, Artificial | 3 | 2021 | 22116 | 0.05 | Why? |
| Disease Management | 1 | 2019 | 6841 | 0.05 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2018 | 5277 | 0.05 | Why? |
| T-Lymphocytes | 1 | 2017 | 6670 | 0.05 | Why? |
| Diabetes Mellitus, Type 2 | 2 | 2021 | 6166 | 0.05 | Why? |
| Pneumonia, Viral | 7 | 2020 | 243684 | 0.05 | Why? |
| Coronavirus Infections | 7 | 2020 | 253789 | 0.05 | Why? |
| Endpoint Determination | 1 | 2021 | 344 | 0.05 | Why? |
| Risk Assessment | 3 | 2018 | 25439 | 0.05 | Why? |
| Antiviral Agents | 3 | 2021 | 41703 | 0.05 | Why? |
| Anti-Bacterial Agents | 1 | 2021 | 10083 | 0.05 | Why? |
| Thrombosis | 1 | 2021 | 7504 | 0.05 | Why? |
| Sample Size | 1 | 2021 | 518 | 0.05 | Why? |
| Sodium Acetate | 1 | 2017 | 3 | 0.04 | Why? |
| Magnesium Chloride | 1 | 2017 | 4 | 0.04 | Why? |
| Health Personnel | 2 | 2018 | 29646 | 0.04 | Why? |
| Ezetimibe | 1 | 2017 | 50 | 0.04 | Why? |
| Global Health | 2 | 2019 | 13911 | 0.04 | Why? |
| Simvastatin | 1 | 2017 | 63 | 0.04 | Why? |
| Potassium Chloride | 1 | 2017 | 24 | 0.04 | Why? |
| Gluconates | 1 | 2017 | 28 | 0.04 | Why? |
| Diastole | 1 | 2018 | 168 | 0.04 | Why? |
| Rosuvastatin Calcium | 1 | 2017 | 89 | 0.04 | Why? |
| Oxygen Inhalation Therapy | 2 | 2021 | 3629 | 0.04 | Why? |
| Early Termination of Clinical Trials | 1 | 2020 | 1256 | 0.04 | Why? |
| Systole | 1 | 2018 | 252 | 0.04 | Why? |
| Enzyme-Linked Immunospot Assay | 1 | 2017 | 325 | 0.04 | Why? |
| Administration, Intravenous | 1 | 2020 | 1115 | 0.04 | Why? |
| Catheter-Related Infections | 1 | 2020 | 381 | 0.04 | Why? |
| Ticlopidine | 1 | 2017 | 193 | 0.04 | Why? |
| Hospital Mortality | 2 | 2017 | 22087 | 0.04 | Why? |
| Hospitalization | 6 | 2021 | 54280 | 0.04 | Why? |
| Laparotomy | 1 | 2017 | 241 | 0.04 | Why? |
| Romania | 1 | 2017 | 590 | 0.04 | Why? |
| Fibrin Fibrinogen Degradation Products | 2 | 2021 | 5993 | 0.04 | Why? |
| Patient Reported Outcome Measures | 1 | 2021 | 912 | 0.04 | Why? |
| Postoperative Period | 1 | 2017 | 651 | 0.03 | Why? |
| Tidal Volume | 1 | 2017 | 565 | 0.03 | Why? |
| Aged, 80 and over | 6 | 2021 | 88759 | 0.03 | Why? |
| Costs and Cost Analysis | 1 | 2019 | 694 | 0.03 | Why? |
| Return to Work | 1 | 2021 | 579 | 0.03 | Why? |
| Ventricular Remodeling | 1 | 2017 | 349 | 0.03 | Why? |
| Factor Xa Inhibitors | 1 | 2019 | 490 | 0.03 | Why? |
| Practice Guidelines as Topic | 1 | 2018 | 15421 | 0.03 | Why? |
| Abdomen | 1 | 2017 | 424 | 0.03 | Why? |
| Organ Dysfunction Scores | 1 | 2020 | 1475 | 0.03 | Why? |
| Adenosine | 1 | 2017 | 509 | 0.03 | Why? |
| Respiratory Therapy | 1 | 2020 | 918 | 0.03 | Why? |
| Standard of Care | 1 | 2020 | 1297 | 0.03 | Why? |
| Patient Acuity | 1 | 2020 | 1755 | 0.03 | Why? |
| Atherosclerosis | 1 | 2021 | 768 | 0.03 | Why? |
| Data Interpretation, Statistical | 1 | 2017 | 657 | 0.03 | Why? |
| Severity of Illness Index | 3 | 2021 | 48226 | 0.03 | Why? |
| Metabolomics | 1 | 2017 | 921 | 0.03 | Why? |
| Telephone | 1 | 2021 | 1705 | 0.03 | Why? |
| Thoracic Surgical Procedures | 1 | 2017 | 504 | 0.03 | Why? |
| Patient Readmission | 1 | 2021 | 1543 | 0.03 | Why? |
| Length of Stay | 2 | 2020 | 11042 | 0.03 | Why? |
| Disease Progression | 2 | 2021 | 13580 | 0.03 | Why? |
| Hydrocortisone | 1 | 2020 | 1790 | 0.03 | Why? |
| Methylprednisolone | 1 | 2020 | 2107 | 0.02 | Why? |
| Flow Cytometry | 1 | 2017 | 2393 | 0.02 | Why? |
| Pneumothorax | 1 | 2017 | 758 | 0.02 | Why? |
| Ventricular Function, Left | 1 | 2017 | 1555 | 0.02 | Why? |
| Social Class | 1 | 2017 | 1360 | 0.02 | Why? |
| Survivors | 1 | 2021 | 2619 | 0.02 | Why? |
| Adolescent | 4 | 2021 | 86841 | 0.02 | Why? |
| Blood Coagulation | 1 | 2021 | 2768 | 0.02 | Why? |
| Coronary Angiography | 1 | 2017 | 2275 | 0.02 | Why? |
| Young Adult | 4 | 2021 | 93724 | 0.02 | Why? |
| Stroke Volume | 1 | 2017 | 2153 | 0.02 | Why? |
| Proteomics | 1 | 2017 | 2481 | 0.02 | Why? |
| Odds Ratio | 1 | 2018 | 5861 | 0.02 | Why? |
| Clinical Protocols | 1 | 2017 | 2734 | 0.02 | Why? |
| Renal Insufficiency, Chronic | 1 | 2021 | 2654 | 0.02 | Why? |
| Risk | 1 | 2018 | 5288 | 0.02 | Why? |
| Patient Discharge | 1 | 2021 | 5696 | 0.02 | Why? |
| Internationality | 1 | 2018 | 3297 | 0.02 | Why? |
| Biomarkers | 2 | 2018 | 23361 | 0.02 | Why? |
| Survival Analysis | 1 | 2018 | 7592 | 0.02 | Why? |
| Predictive Value of Tests | 1 | 2019 | 9537 | 0.02 | Why? |
| Retrospective Studies | 3 | 2020 | 105322 | 0.02 | Why? |
| Electrocardiography | 1 | 2017 | 3957 | 0.02 | Why? |
| Patient Selection | 1 | 2017 | 4560 | 0.01 | Why? |
| Interleukin-6 | 1 | 2020 | 7522 | 0.01 | Why? |
| Magnetic Resonance Imaging | 1 | 2017 | 6551 | 0.01 | Why? |
| Pandemics | 7 | 2020 | 389249 | 0.01 | Why? |
| India | 1 | 2017 | 11875 | 0.01 | Why? |
| Heart Failure | 1 | 2021 | 6638 | 0.01 | Why? |
| Betacoronavirus | 5 | 2020 | 204454 | 0.01 | Why? |
| Infant, Newborn | 1 | 2020 | 23105 | 0.01 | Why? |
| Critical Care | 1 | 2021 | 14081 | 0.01 | Why? |
| Infant | 1 | 2020 | 30274 | 0.01 | Why? |
| Prevalence | 1 | 2019 | 25773 | 0.01 | Why? |
| Comorbidity | 1 | 2021 | 34796 | 0.01 | Why? |
| Child, Preschool | 1 | 2020 | 36283 | 0.01 | Why? |
| Age Factors | 1 | 2017 | 21039 | 0.01 | Why? |
| Child | 1 | 2020 | 70012 | 0.01 | Why? |
| China | 1 | 2017 | 50654 | 0.01 | Why? |
Berwanger's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(232)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(284)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_